tcY-NH2 (trifluoroacetate salt)
(Synonyms: tc-YPGKF-NH2, trans-cinnamoyl-YPGKF-amide, trans-cinnamoyl-YPGKF-NH2) 目录号 : GC52460A peptide antagonist of PAR4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
tcY-NH2 is a synthetic peptide antagonist of proteinase-activated receptor 4 (PAR4) that corresponds to amino acids 1-6 of the amino terminal tethered ligand sequence of mouse PAR4.1 It inhibits platelet aggregation induced by the PAR4 agonist AYPGKF-NH2 in washed isolated rat platelets (IC50 = 95-190 µM), as well as induces relaxation of isolated rat aortic rings precontracted with phenylephrine and contraction of isolated rat gastric longitudinal muscle strips (EC50s = 64 and 1 µM, respectively). tcY-NH2 (400 µM) inhibits thrombin-induced migration of primary hepatocellular carcinoma (HCC) cells.2 It reduces myocardial infarct size as a percentage of the area at risk ex vivo in a isolated rat heart model of ischemia-reperfusion injury.3
1.Hollenberg, M.D., Saifeddine, M., Sandhu, S., et al.Proteinase-activated receptor-4: Evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivoBr. J. Pharmacol.143(4)443-454(2004) 2.Kaufmann, R., Rahn, S., Pollrich, K., et al.Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4J. Cell. Physiol.211(3)699-707(2007) 3.Strande, J.L., Hsu, A., Su, J., et al.Inhibiting protease-activated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signalingJ. Pharmacol. Exp. Ther.324(3)1045-1054(2008)
| Cas No. | SDF | Download SDF | |
| 别名 | tc-YPGKF-NH2, trans-cinnamoyl-YPGKF-amide, trans-cinnamoyl-YPGKF-NH2 | ||
| Canonical SMILES | NC([C@H](CC1=CC=CC=C1)NC([C@H](CCCCN)NC(CNC([C@H]2N(C([C@@H](NC(/C=C/C3=CC=CC=C3)=O)CC4=CC=C(O)C=C4)=O)CCC2)=O)=O)=O)=O.OC(C(F)(F)F)=O | ||
| 分子式 | C40H49N7O7 ? XCF3COOH | 分子量 | 739.9 |
| 溶解度 | DMF: 12 mg/ml,DMSO: 10 mg/ml,Ethanol: 33 mg/ml,PBS (pH 7.2): 1 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3515 mL | 6.7577 mL | 13.5153 mL |
| 5 mM | 0.2703 mL | 1.3515 mL | 2.7031 mL |
| 10 mM | 0.1352 mL | 0.6758 mL | 1.3515 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。